|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van Weelden WJ, Massuger LFAG, ENITE C,
Pijnenborg JMA and Romano A: Anti-estrogen treatment in endometrial
cancer: A systematic review. Front Oncol. 9:3592019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mu N, Zhu Y, Wang Y, Zhang H and Xue F:
Insulin resistance: A significant risk factor of endometrial
cancer. Gynecol Oncol. 125:751–757. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shao Y, Cheng S, Hou J, Zuo Y, Zheng W,
Xia M and Mu N: Insulin is an important risk factor of endometrial
cancer among premenopausal women: A case-control study in China.
Tumour Biol. 37:4721–4726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arthur RS, Kabat GC, Kim MY, Wild RA,
Shadyab AH, Wactawski-Wende J, Ho GYF, Reeves KW, Kuller LH, Luo J,
et al: Metabolic syndrome and risk of endometrial cancer in
postmenopausal women: A prospective study. Cancer Causes Control.
30:355–363. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mu N, Dong M, Liu C, Wang X, Cong J, Wang
L, Wang X, Lakhani I, Liu X, Hou J, et al: Association between
preoperative serum insulin levels and lymph node metastasis in
endometrial cancer-a prospective cohort study. Cancer Med.
7:1519–1527. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Amant F, Moerman P, Neven P, Timmerman D,
Van Limbergen E and Vergote I: Endometrial cancer. Lancet.
366:491–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carneiro MM, Lamaita RM, Ferreira MC and
Silva-Filho AL: Fertility-preservation in endometrial cancer: Is it
safe? Review of the literature. JBRA Assist Reprod. 20:232–239.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koopman E, Blok LJ, Brinkmann AO,
Helmerhorst TJ and Huikeshoven FJ: Differential gene expression in
progesterone-sensitive and progesterone-insensitive endometrial
carcinoma cells. Eur J Obstet Gynecol Reprod Biol. 82:135–138.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marjoribanks J, Farquhar C, Roberts H,
Lethaby A and Lee J: Long-term hormone therapy for perimenopausal
and postmenopausal women. Cochrane Database Syst Rev.
1:CD0041432017.PubMed/NCBI
|
|
11
|
Mallik R and Chowdhury TA: Metformin in
cancer. Diabetes Res Clin Pract. 143:409–419. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gadducci A, Biglia N, Tana R, Cosio S and
Gallo M: Metformin use and gynecological cancers: A novel treatment
option emerging from drug repositioning. Crit Rev Oncol Hematol.
105:73–83. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamana H, Kato K, Kobara H, Fujihara S,
Fujita K, Namima D, Fujita N, Kobayashi K, Kamada H, Morishita A,
et al: Metformin inhibits proliferation and tumor growth of QGP-1
pancreatic neuroendocrine tumor cells by inducing cell cycle arrest
and apoptosis. Anticancer Res. 40:121–132. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Klubo-Gwiezdzinska J, Jensen K, Costello
J, Patel A, Hoperia V, Bauer A, Burman KD, Wartofsky L and Vasko V:
Metformin inhibits growth and decreases resistance to anoikis in
medullary thyroid cancer cells. Endocr Relat Cancer. 19:447–456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu S, Yue C, Chen H, Chen Y and Li G:
Metformin promotes Beclin1-Dependent autophagy to inhibit the
progression of gastric cancer. Onco Targets Ther. 13:4445–4455.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye J, Qi L, Chen K, Li R, Song S, Zhou C
and Zhai W: Metformin induces TPC-1 cell apoptosis through
endoplasmic reticulum stress-associated pathways in vitro and in
vivo. Int J Oncol. 55:331–339. 2019.PubMed/NCBI
|
|
17
|
Mu N, Dong M, Li L, Xia M, Qv L, Wang Y,
Dong C, Chen Y, Zuo Y, Hou J and Xue F: Synergistic effect of
metformin and medroxyprogesterone 17acetate on the development of
endometrial cancer. Oncol Rep. 39:2015–2021. 2018.PubMed/NCBI
|
|
18
|
Hari Kumar KVS: The good, the bad, and the
ugly facets of insulin resistance. Med J Armed Forces India.
76:4–7. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luc K, Schramm-Luc A, Guzik TJ and
Mikolajczyk TP: Oxidative stress and inflammatory markers in
prediabetes and diabetes. J Physiol Pharmacol. 70:809–824.
2019.
|
|
20
|
Patel TP, Rawal K, Bagchi AK, Akolkar G,
Bernardes N, Dias DDS, Gupta S and Singal PK: Insulin resistance:
An additional risk factor in the pathogenesis of cardiovascular
disease in type 2 diabetes. Heart Fail Rev. 21:11–23. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang C, Qu H, Zhao X, Hu Y, Xiong J, Jiang
X, Chen Y and Li Z: Plasma secretagogin is increased in individuals
with glucose dysregulation. Exp Clin Endocrinol Diabetes. Sep
23–2019.(Epub ahead of print). doi: 10.1055/a-1001-2244.
|
|
22
|
Kheirandish M, Mahboobi H, Yazdanparast M,
Kamal W and Kamal MA: Anti-cancer effects of metformin: Recent
evidences for its role in prevention and treatment of cancer. Curr
Drug Metab. 19:793–797. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eritja N, Mirantes C, Llobet D, Yeramian
A, Bergadà L, Dosil MA, Domingo M, Matias-Guiu X and Dolcet X:
Long-term estradiol exposure is a direct mitogen for
insulin/EGF-primed endometrial cells and drives PTEN loss-induced
hyperplasic growth. Am J Pathol. 183:277–287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arcidiacono B, Iiritano S, Nocera A,
Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E and Brunetti
A: Insulin resistance and cancer risk: An overview of the
pathogenetic mechanisms. Exp Diabetes Res. 2012:7891742012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kliemann N, Murphy N, Viallon V, Freisling
H, Tsilidis KK, Rinaldi S, Mancini FR, Fagherazzi G, Boutron-Ruault
MC, Boeing H, et al: Predicted basal metabolic rate and cancer risk
in the European prospective investigation into cancer and
nutrition. Int J Cancer. 147:648–661. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bjorge T, Haggstrom C, Ghaderi S, Nagel G,
Manjer J, Tretli S, Ulmer H, Harlid S, Rosendahl AH, Lang A, et al:
BMI and weight changes and risk of obesity-related cancers: A
pooled European cohort study. Int J Epidemiol. 48:1872–1885. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lai Y and Sun C: Association of abnormal
glucose metabolism and insulin resistance in patients with atypical
and typical endometrial cancer. Oncol Lett. 15:2173–2178.
2018.PubMed/NCBI
|
|
29
|
Xu WH, Matthews CE, Xiang YB, Zheng W,
Ruan ZX, Cheng JR, Gao YT and Shu XO: Effect of adiposity and fat
distribution on endometrial cancer risk in Shanghai women. Am J
Epidemiol. 161:939–947. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoon YS, Kwon AR, Lee YK and Oh SW:
Circulating adipokines and risk of obesity related cancers: A
systematic review and meta-analysis. Obes Res Clin Pract.
13:329–339. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Che Q, Xiao X, Liu M, Lu Y, Dong X and Liu
S: IL-6 promotes endometrial cancer cells invasion and migration
through signal transducers and activators of transcription 3
signaling pathway. Pathol Res Pract. 215:1523922019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Y, Hua S, Tian W, Zhang L, Zhao J,
Zhang H, Zhang W and Xue F: Mitogenic and anti-apoptotic effects of
insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt
dependent. Gynecol Oncol. 125:734–741. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gunter MJ, Hoover DR, Yu H,
Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X,
Ho GY, et al: A prospective evaluation of insulin and insulin-like
growth factor-I as risk factors for endometrial cancer. Cancer
Epidemiol Biomarkers Prev. 17:921–929. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Anastasi E, Filardi T, Tartaglione S,
Lenzi A, Angeloni A and Morano S: Linking type 2 diabetes and
gynecological cancer: An introductory overview. Clin Chem Lab Med.
56:1413–1425. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang X and Wang J: The role of metabolic
syndrome in endometrial cancer: A review. Front Oncol. 9:7442019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
MacKintosh ML, Derbyshire AE, McVey RJ,
Bolton J, Nickkho-Amiry M, Higgins CL, Kamieniorz M, Pemberton PW,
Kirmani BH, Ahmed B, et al: The impact of obesity and bariatric
surgery on circulating and tissue biomarkers of endometrial cancer
risk. Int J Cancer. 144:641–650. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mitsuhashi A, Kiyokawa T, Sato Y and Shozu
M: Effects of metformin on endometrial cancer cell growth in vivo:
A preoperative prospective trial. Cancer. 120:2986–2995. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang K, Luo Y, Dai H and Deng Z: Effects
of bariatric surgery on cancer risk: Evidence from meta-analysis.
Obes Surg. 30:1265–1272. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Soliman PT, Zhang Q, Broaddus RR, Westin
SN, Iglesias D, Munsell MF, Schmandt R, Yates M, Ramondetta L and
Lu KH: Prospective evaluation of the molecular effects of metformin
on the endometrium in women with newly diagnosed endometrial
cancer: A window of opportunity study. Gynecol Oncol. 143:466–471.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yates MS, Coletta AM, Zhang Q, Schmandt
RE, Medepalli M, Nebgen D, Soletsky B, Milbourne A, Levy E, Fellman
B, et al: Prospective randomized biomarker study of metformin and
lifestyle intervention for prevention in obese women at increased
risk for endometrial cancer. Cancer Prev Res (Phila). 11:477–490.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vallianou NG, Evangelopoulos A and Kazazis
C: Metformin and cancer. Rev Diabet Stud. 10:228–235. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang Y, An H, Liu T, Qin C, Sesaki H, Guo
S, Radovick S, Hussain M, Maheshwari A, Wondisford FE, et al:
Metformin improves mitochondrial respiratory activity through
activation of AMPK. Cell Rep. 29:1511–1523 e5. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jiang S, Wang Y, Luo L, Shi F, Zou J, Lin
H, Ying Y, Luo Y, Zhan Z, Liu P, et al: AMP-activated protein
kinase regulates cancer cell growth and metabolism via nuclear and
mitochondria events. J Cell Mol Med. 23:3951–3961. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pena CG, Nakada Y, Saatcioglu HD, Aloisio
GM, Cuevas I, Zhang S, Miller DS, Lea JS, Wong KK, DeBerardinis RJ,
et al: LKB1 loss promotes endometrial cancer progression via
CCL2-dependent macrophage recruitment. J Clin Invest.
125:4063–4076. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Saraei P, Asadi I, Kakar MA and Moradi-Kor
N: The beneficial effects of metformin on cancer prevention and
therapy: A comprehensive review of recent advances. Cancer Manag
Res. 11:3295–3313. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
El-Sisi AE, Sokar SS, El-Sayad ME, Moussa
EA and Salim EI: Anticancer effect of metformin against
2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine-induced rat
mammary carcinogenesis is through AMPK pathway and modulation of
oxidative stress markers. Hum Exp Toxicol. 38:703–712. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation-implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pabona JMP, Burnett AF, Brown DM, Quick
CM, Simmen FA, Montales MTE, Liu SJ, Rose T, Alhallak I, Siegel ER
and Simmen RC: Metformin promotes anti-tumor biomarkers in human
endometrial cancer cells. Reprod Sci. 27:267–277. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Iglesias DA, Yates MS, van der Hoeven D,
Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J,
Bowser J, et al: Another surprise from Metformin: Novel mechanism
of action via K-Ras influences endometrial cancer response to
therapy. Mol Cancer Ther. 12:2847–2856. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Guo H, Kong W, Zhang L, Han J, Clark LH,
Yin Y, Fang Z, Sun W, Wang J, Gilliam TP, et al: Reversal of
obesity-driven aggressiveness of endometrial cancer by metformin.
Am J Cancer Res. 9:2170–2193. 2019.PubMed/NCBI
|
|
52
|
Moroi AJ and Watson SP: Impact of the
PI3-kinase/Akt pathway on ITAM and hemITAM receptors: Haemostasis,
platelet activation and antithrombotic therapy. Biochem Pharmacol.
94:186–194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Guo S, Loibl S, von Minckwitz G,
Darb-Esfahani S, Lederer B and Denkert C: PIK3CA H1047R mutation
associated with a lower pathological complete response rate in
triple-negative breast cancer patients treated with
anthracycline-taxane-based neoadjuvant chemotherapy. Cancer Res
Treat. 52:689–696. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jhanwar-Uniyal M, Wainwright JV, Mohan AL,
Tobias ME, Murali R, Gandhi CD and Schmidt MH: Diverse signaling
mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a
formidable relationship. Adv Biol Regul. 72:51–62. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Johnston SB and Raines RT: Catalysis by
the tumor-suppressor enzymes PTEN and PTEN-L. PLoS One.
10:e01168982015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kim SM, Nguyen TT, Ravi A, Kubiniok P,
Finicle BT, Jayashankar V, Malacrida L, Hou J, Robertson J, Gao D,
et al: PTEN Deficiency and AMPK activation promote nutrient
scavenging and anabolism in prostate cancer cells. Cancer Discov.
8:866–883. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Leitner MG, Hobiger K, Mavrantoni A, Feuer
A, Oberwinkler J, Oliver D and Halaszovich CR: A126 in the active
site and TI167/168 in the TI loop are essential determinants of the
substrate specificity of PTEN. Cell Mol Life Sci. 75:4235–4250.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Salvesen HB, Werner HM and Krakstad C:
PI3K pathway in gynecologic malignancies. Am Soc Clin Oncol Educ
Book. Jun 31–2013.(Epub ahead of print). doi:
10.1200/EdBook_AM.2013.33.e218. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Mackay HJ, Eisenhauer EA, Kamel-Reid S,
Tsao M, Clarke B, Karakasis K, Werner HM, Trovik J, Akslen LA,
Salvesen HB, et al: Molecular determinants of outcome with
mammalian target of rapamycin inhibition in endometrial cancer.
Cancer. 120:603–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
de Melo AC, Paulino E and Garces AH: A
review of mTOR pathway inhibitors in gynecologic cancer. Oxid Med
Cell Longev. 2017:48097512017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kosmas K, Mitropoulou G, Provatas I,
Stamoulas M and Marouga A: Expression of phosphatase and tensin
homologue in imprint smears of endometrial carcinoma.
Cytopathology. 29:558–564. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Roncolato F, Lindemann K, Willson ML,
Martyn J and Mileshkin L: PI3K/AKT/mTOR inhibitors for advanced or
recurrent endometrial cancer. Cochrane Database Syst Rev.
10:CD0121602019.PubMed/NCBI
|
|
64
|
Saini N and Yang X: Metformin as an
anti-cancer agent: Actions and mechanisms targeting cancer stem
cells. Acta Biochim Biophys Sin (Shanghai). 50:133–143. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Qiang P, Shao Y, Sun YP, Zhang J and Chen
LJ: Metformin inhibits proliferation and migration of endometrial
cancer cells through regulating PI3K/AKT/MDM2 pathway. Eur Rev Med
Pharmacol Sci. 23:1778–1785. 2019.PubMed/NCBI
|
|
66
|
Kasprzak A, Kwasniewski W, Adamek A and
Gozdzicka-Jozefiak A: Insulin-like growth factor (IGF) axis in
cancerogenesis. Mutat Res Rev Mutat Res. 772:78–104. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang Y, Li MX, Wang H, Zeng Z and Li XM:
Metformin down-regulates endometrial carcinoma cell secretion of
IGF-1 and expression of IGF-1R. Asian Pac J Cancer Prev.
16:221–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Tandon M, Chen Z, Othman AH and Pratap J:
Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth,
survival and sensitivity towards metformin in breast cancer bone
metastasis. Oncogene. 35:4730–4740. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chen G, Yuan C, Duan F, Liu Y, Zhang J, He
Z, Huang H, He C and Wang H: IGF1/MAPK/ERK signaling
pathway-mediated programming alterations of adrenal cortex cell
proliferation by prenatal caffeine exposure in male offspring rats.
Toxicol Appl Pharmacol. 341:64–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wang CF, Zhang G, Zhao LJ, Qi WJ, Li XP,
Wang JL and Wei LH: Overexpression of the insulin receptor isoform
A promotes endometrial carcinoma cell growth. PLoS One.
8:e690012013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Shehab MA, Biggar K, Singal SS, Nygard K,
Shun-Cheng Li S, Jansson T and Gupta MB: Exposure of decidualized
HIESC to low oxygen tension and leucine deprivation results in
increased IGFBP-1 phosphorylation and reduced IGF-I bioactivity.
Mol Cell Endocrinol. 452:1–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Xie Y, Wang JL, Ji M, Yuan ZF, Peng Z,
Zhang Y, Wen JG and Shi HR: Regulation of insulin-like growth
factor signaling by metformin in endometrial cancer cells. Oncol
Lett. 8:1993–1999. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Du J, Shi HR, Ren F, Wang JL, Wu QH, Li X
and Zhang RT: Inhibition of the IGF signaling pathway reverses
cisplatin resistance in ovarian cancer cells. BMC Cancer.
17:8512017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cai D, Sun H, Qi Y, Zhao X, Feng M and Wu
X: Insulin-Like growth factor 1/mammalian target of rapamycin and
AMP-Activated protein kinase signaling involved in the effects of
metformin in the human endometrial cancer. Int J Gynecol Cancer.
26:1667–1672. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Cao C, Zhou JY, Xie SW, Guo XJ, Li GT,
Gong YJ, Yang WJ, Li Z, Zhong RH, Shao HH and Zhu Y: Metformin
enhances nomegestrol acetate suppressing growth of endometrial
cancer cells and may correlate to downregulating mTOR activity in
vitro and in vivo. Int J Mol Sci. 20:33082019. View Article : Google Scholar
|
|
76
|
Xu HL, Xu WH, Cai Q, Feng M, Long J, Zheng
W, Xiang YB and Shu XO: Polymorphisms and haplotypes in the
caspase-3, caspase-7, and caspase-8 genes and risk for endometrial
cancer: A population-based, case-control study in a Chinese
population. Cancer Epidemiol Biomarkers Prev. 18:2114–2122. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
McComb S, Chan PK, Guinot A,
Hartmannsdottir H, Jenni S, Dobay MP, Bourquin JP and Bornhauser
BC: Efficient apoptosis requires feedback amplification of upstream
apoptotic signals by effector caspase-3 or −7. Sci Adv.
5:eaau94332019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Aral K, Aral CA and Kapila Y: The role of
caspase-8, caspase-9, and apoptosis inducing factor in periodontal
disease. J Periodontol. 90:288–294. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Jang JH, Song IH, Sung EG, Lee TJ and Kim
JY: Metformin-induced apoptosis facilitates degradation of the
cellular caspase 8 (FLICE)-like inhibitory protein through a
caspase-dependent pathway in human renal cell carcinoma A498 cells.
Oncol Lett. 16:2030–2038. 2018.PubMed/NCBI
|
|
80
|
Zhao Y, Luo Q, Mo J, Li J, Ye D, Ao Z,
Chen L and Liu J: Metformin in combination with JS-K inhibits
growth of renal cell carcinoma cells via reactive oxygen species
activation and inducing DNA breaks. J Cancer. 11:3701–3712. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhou X, Zhang P and Wang Q, Ji N, Xia S,
Ding Y and Wang Q: Metformin ameliorates experimental diabetic
periodontitis independently of mammalian target of rapamycin (mTOR)
inhibition by reducing NIMA-related kinase 7 (Nek7) expression. J
Periodontol. 90:1032–1042. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Guo Y, Yuan J, Yin S, Wang X, Shuai R and
Kang J: MAP2K6-FP enhances the sensitiveness of paclitaxel for
ovarian cancer via inducing autophagy. Int J Gynecol Cancer.
27:1082–1087. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Giatromanolaki A, Koukourakis MI,
Koutsopoulos A, Chloropoulou P, Liberis V and Sivridis E: High
Beclin 1 expression defines a poor prognosis in endometrial
adenocarcinomas. Gynecol Oncol. 123:147–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Bermudez M, Aguilar-Medina M,
Lizarraga-Verdugo E, Avendaño-Félix M, Silva-Benítez E,
López-Camarillo C and Ramos-Payán R: LncRNAs as regulators of
autophagy and drug resistance in colorectal cancer. Front Oncol.
9:10082019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ran X, Zhou P and Zhang K: Autophagy plays
an important role in stemness mediation and the novel dual function
of EIG121 in both autophagy and stemness regulation of endometrial
carcinoma JEC cells. Int J Oncol. 51:644–656. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tomic T, Botton T, Cerezo M, Robert G,
Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder
JM, et al: Metformin inhibits melanoma development through
autophagy and apoptosis mechanisms. Cell Death Dis. 2:e1992011.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang D, Xuan J, Zheng BB, Zhou YL, Lin Y,
Wu YS, Zhou YF, Huang YX, Wang Q, Shen LY, et al: Metformin
improves functional recovery after spinal cord injury via autophagy
flux stimulation. Mol Neurobiol. 54:3327–3341. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Takahashi A, Kimura F, Yamanaka A,
Takebayashi A, Kita N, Takahashi K and Murakami T: Metformin
impairs growth of endometrial cancer cells via cell cycle arrest
and concomitant autophagy and apoptosis. Cancer Cell Int.
14:532014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zou G, Bai J, Li D and Chen Y: Effect of
metformin on the proliferation, apoptosis, invasion and autophagy
of ovarian cancer cells. Exp Ther Med. 18:2086–2094.
2019.PubMed/NCBI
|
|
90
|
Tseng CH: Metformin and endometrial cancer
risk in Chinese women with type 2 diabetes mellitus in Taiwan.
Gynecol Oncol. 138:147–153. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Franchi M, Asciutto R, Nicotra F, Merlino
L, La Vecchia C, Corrao G and Bosetti C: Metformin, other
antidiabetic drugs, and endometrial cancer risk: A nested
case-control study within Italian healthcare utilization databases.
Eur J Cancer Prev. 26:225–231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Ko EM, Walter P, Jackson A, Clark L,
Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA
and Bae-Jump V: Metformin is associated with improved survival in
endometrial cancer. Gynecol Oncol. 132:438–442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Rossi A, Garber CE, Ortiz M, Shankar V,
Goldberg GL and Nevadunsky NS: Feasibility of a physical activity
intervention for obese, socioculturally diverse endometrial cancer
survivors. Gynecol Oncol. 142:304–310. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Clement NS, Oliver TR, Shiwani H, Sanner
JR, Mulvaney CA and Atiomo W: Metformin for endometrial
hyperplasia. Cochrane Database Syst Rev. 10:CD0122142017.PubMed/NCBI
|
|
95
|
Mitsuhashi A, Sato Y, Kiyokawa T,
Koshizaka M, Hanaoka H and Shozu M: Phase II study of
medroxyprogesterone acetate plus metformin as a fertility-sparing
treatment for atypical endometrial hyperplasia and endometrial
cancer. Ann Oncol. 27:262–266. 2016. View Article : Google Scholar : PubMed/NCBI
|
